Prothena Co. plc (NASDAQ:PRTA – Free Report) – Analysts at Zacks Research upped their Q2 2024 earnings per share (EPS) estimates for Prothena in a research report issued on Monday, May 27th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will earn ($1.22) per share for the quarter, up from their previous […]
Shares of Prothena Co. plc (NASDAQ:PRTA – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month […]
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target
Prothena will.
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will
Shares of Prothena Co. plc (NASDAQ:PRTA – Get Free Report) have been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average […]